227
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah’s Witnesses patients: a feasible option in the age of hematopoietic growth factors

, , , , , , , , & show all
Pages 2324-2327 | Received 16 Nov 2018, Accepted 16 Jan 2019, Published online: 18 Feb 2019

References

  • Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541–1552.
  • Berend K, Levi M. Management of adult Jehovah's Witness patients with acute bleeding. Am J Med. 2009;122:1071–1076.
  • Bodnaruk ZM, Wong CJ, Thomas MJ. Meeting the clinical challenge of care for Jehovah's Witnesses. Transfus Med Rev. 2004;18:105–116.
  • Vasques F, Kinnunen E-M, Pol M, et al. Outcome of Jehovah’s Witnesses after adult cardiac surgery: systematic review and meta-analysis of comparative studies. Transfusion. 2016;56:2146–2153.
  • Nash MJ, Cohen H. Management of Jehovah's Witness patients with haematological problems. Blood Rev. 2004;18:211–217.
  • Couturier M-A, Huguet F, Chevallier P, et al. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience. Am J Hematol. 2015;90:986–991.
  • Maury S, Chevret S, Thomas X, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375:1044–1053.
  • Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. Jco. 2009;27:911–918.
  • Goldberg SL, Chan CS, Dawkins FW, et al. Should Jehovah's Witnesses be denied intensive chemotherapy for acute leukemia? N Engl J Med. 1990;322:777–778.
  • Hargis JB, Waddell DJ, Diehl L, et al. Induction chemotherapy in Jehovah's Witnesses with leukaemia. Lancet. 1990;336:563–564.
  • Cullis JO, Duncombe AS, Dudley JM, et al. Acute leukaemia in Jehovah's Witnesses. Br J Haematol. 1998;100:664–668.
  • Jillella AP, Arellano ML, Heffner LT, et al. Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s Witness congregation. Hematol Rep. 2017;9:7083.
  • Donahue LL, Shapira I, Shander A, et al. Management of acute anemia in a Jehovah’s Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin-based oxygen carrier: a case report and review of literature. Transfusion. 2010;50:1561–1567.
  • Al-Nawakil C, Quarre M-C, Heshmati F, et al. Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. Br J Haematol. 2013;161:738–740.
  • Laszlo D, Agazzi A, Goldhirsch A, et al. Tailored therapy of adult acute leukaemia in Jehovah’s Witnesses: unjustified reluctance to treat. Eur J Haematol. 2004;72:264–267.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.